These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 28342316

  • 1. Comparison of cytomegalovirus (CMV)-specific neutralization capacity of hyperimmunoglobulin (HIG) versus standard intravenous immunoglobulin (IVIG) preparations: Impact of CMV IgG normalization.
    Schampera MS, Schweinzer K, Abele H, Kagan KO, Klein R, Rettig I, Jahn G, Hamprecht K.
    J Clin Virol; 2017 May; 90():40-45. PubMed ID: 28342316
    [Abstract] [Full Text] [Related]

  • 2. Role of pentamer complex-specific and IgG subclass 3 antibodies in HCMV hyperimmunoglobulin and standard intravenous IgG preparations.
    Schampera MS, Arellano-Galindo J, Kagan KO, Adler SP, Jahn G, Hamprecht K.
    Med Microbiol Immunol; 2019 Feb; 208(1):69-80. PubMed ID: 30203132
    [Abstract] [Full Text] [Related]

  • 3. Functional Properties of Human Cytomegalovirus Hyperimmunoglobulin and Standard Immunoglobulin Preparations.
    Germer M, Herbener P, Schüttrumpf J.
    Ann Transplant; 2016 Sep 06; 21():558-64. PubMed ID: 27595792
    [Abstract] [Full Text] [Related]

  • 4. In vitro evaluation of cytomegalovirus-specific hyperimmune globulins vs. standard intravenous immunoglobulins.
    Miescher SM, Huber TM, Kühne M, Lieby P, Snydman DR, Vensak JL, Berger M.
    Vox Sang; 2015 Jul 06; 109(1):71-8. PubMed ID: 25766313
    [Abstract] [Full Text] [Related]

  • 5. Functional differences between antiviral activities of sulfonated and intact intravenous immunoglobulin preparations toward varicella-zoster virus and cytomegalovirus.
    Yajima M, Shiraki A, Daikoku T, Oyama Y, Yoshida Y, Shiraki K.
    J Infect Chemother; 2015 Jun 06; 21(6):427-33. PubMed ID: 25824903
    [Abstract] [Full Text] [Related]

  • 6. Interaction of Immunoglobulin with Cytomegalovirus-Infected Cells.
    Aiba N, Shiraki A, Yajima M, Oyama Y, Yoshida Y, Ohno A, Yamada H, Takemoto M, Daikoku T, Shiraki K.
    Viral Immunol; 2017 Sep 06; 30(7):500-507. PubMed ID: 28598267
    [Abstract] [Full Text] [Related]

  • 7. Cytomegalovirus neutralization by hyperimmune and standard intravenous immunoglobulin preparations.
    Planitzer CB, Saemann MD, Gajek H, Farcet MR, Kreil TR.
    Transplantation; 2011 Aug 15; 92(3):267-70. PubMed ID: 21659947
    [Abstract] [Full Text] [Related]

  • 8. Measurement and assessment of cytomegalovirus of immunoglobulin (Ig) g titer in preparations.
    Shibaguchi H, Yamamoto T, Kuroki M, Futagami K.
    Yakugaku Zasshi; 2010 Jul 15; 130(7):977-82. PubMed ID: 20606378
    [Abstract] [Full Text] [Related]

  • 9. Binding and neutralizing anti-cytomegalovirus activities in immune globulin products.
    Wang X, Xu Y, Scott DE, Murata H, Struble EB.
    Biologicals; 2017 Nov 15; 50():35-41. PubMed ID: 29029807
    [Abstract] [Full Text] [Related]

  • 10. An enzyme immunoassay based micro-neutralization test for titration of antibodies to human cytomegalovirus (CMV) and its correlation with direct ELISA measuring CMV IgG antibodies.
    Gupta CK, Leszczynski J, Gupta RK, Siber GR.
    Biologicals; 1996 Mar 15; 24(1):41-9. PubMed ID: 8733600
    [Abstract] [Full Text] [Related]

  • 11. Intrafamilial transmission of human cytomegalovirus (HCMV): long-term dynamics of epitope-specific antibody response in context of avidity maturation.
    Hamprecht K, Bissinger AL, Arellano-Galindo J, Schweinzer K, Jiang X, Göhring K, Mikeler E, Jahn G.
    J Clin Virol; 2014 Jun 15; 60(2):119-26. PubMed ID: 24742599
    [Abstract] [Full Text] [Related]

  • 12. Assessment of the presence of cytomegalovirus-neutralizing antibody by a plaque-reduction assay.
    Lewis RB, Matzke DS, Albrecht TB, Pollard RB.
    Rev Infect Dis; 1986 Jun 15; 8 Suppl 4():S434-8. PubMed ID: 3018894
    [Abstract] [Full Text] [Related]

  • 13. Improvement of cytomegalovirus avidity testing by adjusting the concentration of CMV-specific IgG in test samples.
    Dangel V, Bäder U, Enders G.
    J Clin Virol; 2006 Mar 15; 35(3):303-9. PubMed ID: 16298547
    [Abstract] [Full Text] [Related]

  • 14. IgG subclass antibodies to human cytomegalovirus (CMV) in normal human plasma samples and immune globulins and their neutralizing activities.
    Gupta CK, Leszczynski J, Gupta RK, Siber GR.
    Biologicals; 1996 Jun 15; 24(2):117-24. PubMed ID: 8889058
    [Abstract] [Full Text] [Related]

  • 15. Viral Persistence Induces Antibody Inflation without Altering Antibody Avidity.
    Welten SPM, Redeker A, Toes REM, Arens R.
    J Virol; 2016 May 15; 90(9):4402-4411. PubMed ID: 26889035
    [Abstract] [Full Text] [Related]

  • 16. Circulating cytomegalovirus (CMV) neutralizing activity in bone marrow transplant recipients: comparison of passive immunity in a randomized study of four intravenous IgG products administered to CMV-seronegative patients.
    Filipovich AH, Peltier MH, Bechtel MK, Dirksen CL, Strauss SA, Englund JA.
    Blood; 1992 Nov 15; 80(10):2656-60. PubMed ID: 1330079
    [Abstract] [Full Text] [Related]

  • 17. Serum concentrations of immunoglobulins and of antibody isotypes in bone marrow transplant recipients treated with high doses of polyspecific immunoglobulin or with cytomegalovirus hyperimmune globulin.
    Gratwohl A, Doran JE, Bachmann P, Scherz R, Späth P, Baumgartner C, Perret B, Berger C, Nissen C, Tichelli A.
    Bone Marrow Transplant; 1991 Oct 15; 8(4):275-82. PubMed ID: 1661632
    [Abstract] [Full Text] [Related]

  • 18. Antiviral function and efficacy of polyvalent immunoglobulin products against CMV isolates in different human cell lines.
    Frenzel K, Ganepola S, Michel D, Thiel E, Krüger DH, Uharek L, Hofmann J.
    Med Microbiol Immunol; 2012 Aug 15; 201(3):277-86. PubMed ID: 22297735
    [Abstract] [Full Text] [Related]

  • 19. Use of cytomegalovirus hyperimmunoglobulin for prevention of congenital cytomegalovirus disease: a retrospective analysis.
    Buxmann H, Stackelberg OM, Schlößer RL, Enders G, Gonser M, Meyer-Wittkopf M, Hamprecht K, Enders M.
    J Perinat Med; 2012 Mar 27; 40(4):439-46. PubMed ID: 22752777
    [Abstract] [Full Text] [Related]

  • 20. Properties of IgG subclasses to human cytomegalovirus.
    Gilljam G, Wahren B.
    J Virol Methods; 1989 Aug 27; 25(2):139-51. PubMed ID: 2550502
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.